Changes of Apoptosis, p53, and bcl-2 by Irradiation in Poorly Differentiated Thyroid Carcinoma Cell Lines: A Prognostic Marker for the Prospect of Therapeutic Success?

Thyroid

Volumn 20, Issue 2, 2010, Pages 159-166

  Pohl, Fabian ^a   Grosse, Jirka ^a   Grimm, Daniela ^b,c   Brockhoff, Gero ^a   Westphal, Kriss ^c   Moosbauer, Jutta ^a   Koelbl, Oliver ^a   Infanger, Manfred ^c   Eilles, Christoph ^a   Schoenberger, Johann ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b AARHUS UNIVERSITY   (Denmark)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN CELL; IRRADIATION; PRIORITY JOURNAL; THYROID CARCINOMA;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; THYROID NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77149160041     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0345     Document Type: Article

References (39)

1. Nix P, Nicolaides A, Coatesworth AP 2005 Thyroid cancer review 2: management of differentiated thyroid cancers. Int J Clin Pract 59:1459-1463. (Pubitemid 43922634)
2. Hansen KE, Roach M III 2007 Handbook of Evidence-Based Radiation Oncology. Springer, Heidelberg, pp 136-143.
3. Wannenmacher M, Debus J, Wenz F 2006 Strahlentherapie. Springer, Heidelberg, p 439.
4. Sakamoto A, Kasain, Sugano H 1983 Poorly differentiated carcinoma of the thyroid. A clinicopathologic entity for a high-risk group of papillary and follicular carcinomas. Cancer 52:1849-1855.
5. Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM, Lloyd RV 2001 Solid variant of papillary thyroid carcinoma: incidence, clinical-pathologic characteristics, molecular analysis, and biologic behavior. Am J Surg Pathol 25:1478-1484.
6. Burman KD, Ringel MD, Wartofsky L 1996 Unusual types of thyroid neoplasms. Endocrinol Metab Clin North Am 25:49-68.
7. Pulcrano M, Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De Vathaire F, Schlumberger M 2007 Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid 17:639-646.
8. Elkind MM, Whitmore GF 1968 The radiobiology of cultured mammalian cells. Science 161:152.
9. Herrmann T, Baumann M 1997 Klinische Strahlenbiologie 3. Aufl. Gustav Fischer Verlag, Jena, pp 43-45.
10. Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M 2003 CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22:8233-8245.
11. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P 1989 Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708.
12. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest 91:1753-1760.
13. Fagin J, Matsuo K, Karmakar A, Chen D, Tang S, Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184.
14. Hengartner MO 2000 The biochemistry of apoptosis. Nature 407:770-776.
15. Adams JM, Cory S 1998 The bcl-2-protein family: arbiters of cell survival. Science 281:1322-1326.
16. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA 1994 Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 172:337-342.
17. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ 1991 BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961-6965.
18. Lu QL, Abel P, Foster CS, Lalani EN 1996 bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 27:102-110.
19. McDonnell T, Deant N, Platt F 1989 bcl-2 immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79-88.
20. Schönberger J, Bauer J, Spruss T, Weber G, Chahoud I, Eilles C, Grimm D 2000 Establishment and characterization of the follicular thyroid carcinoma cell line ML-1. J Mol Med 78:102-110.
21. Goretzki PE, Frilling A, Simon D, Roeher HD 1990 Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 118:48-63.
22. Jossart GH, Epstein HD, Shaver JK, Weier HU, Greulich KM, Tezelman S, Grossman RF, Siperstein AE, Duh QY, Clark OH 1996 Immunocytochemical detection of p53 in human thyroid carcinomas is associated with mutation and immortalization of cell lines. J Clin Endocrinol Metab 81:3498-3504.
23. Rath GM, Schneider C, Dedieu S, Rothhut B, Soula-Rothhut M, Ghoneim C, Sid B, Morjani H, El Btaouri H, Martiny L 2006 The C-terminal CD47/IAP-binding domain of thrombospondin-1 prevents camptothecin- and doxorubicininduced apoptosis in human thyroid carcinoma cells. Biochim Biophys Acta 1763:1125-1134.
24. Pohl F, Hassel S, Nohe A, Flentje M, Knaus P, Sebald W, Koelbl O 2003 Radiation-induced suppression of the Bmp2 signal transduction pathway in the pluripotent mesenchymal cell line C2C12: an in vitro model for prevention of heterotopic ossification by radiotherapy. Radiat Res 159: 345-350.
25. Schuck A, Poremba C, Lanvers C, Könemann S, Schleifer T, Wai D, Horn K, Hesselmann S, Braun Y, Frodermann B, Schäfer KL, Diallo RI, Rübe CE, Rübe C, Dockhorn- Dworniczak B, Willich N 2002 Radiation-induced changes of telomerase activity in a human Ewing xenograft tumor. Strahlenther Onkol 178:701-708.
26. Gavrieli Y, Sherman Y, Ben-Sasson S 1992 Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493-501.
27. Infanger M, Kossmehl P, Shakibaei M, Baatout S, Witzing A, Grosse J, Bauer J, Cogoli A, Faramarzi S, Derradji H, Neefs M, Paul M, Grimm D 2006 Induction of three-dimensional assembly and increase in apoptosis of human endothelial cells by simulated microgravity: impact of vascular endothelial growth factor. Apoptosis 11:749-764.
28. Grimm D, Bauer J, Kossmehl P, Shakibaei M, Schonberger J, Pickenhahn H, Schulze-Tanzil G, Vetter R, Eilles C, Paul M, Cogoli A 2002 Simulated microgravity alters differentiation and increases apoptosis in human follicular thyroid carcinoma cells. FASEB J 16:604-606.
29. Kossmehl P, Kurth E, Faramarzi S, Habighorst B, Shakibaei M, Wehland M, Kreutz R, Infanger M, Danser AHJ, Grosse J, Paul M, Grimm D 2006 Mechanisms of apoptosis after ischemia and reperfusion: role of the renin-angiotensin system. Apoptosis 11:347-358.
30. Brockhoff G 2009 Flow cytometric DNA und proliferation analysis. In: Sack U, Rothe G (eds) Cellular Diagnostics- Principles, Methods and Clinical Applications in Flow Cytometry. Karger Publishing, Basel, pp 90-425.
31. Gamble SC, Cook MC, Riches AW, Herceg Z, Byrant PE, Arand LE 1999 p53-mutations in tumors derived from irradiated human thyroid epithelial cells. Mutat Res 425:231-238.
32. Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F 1996 Bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer 73:139-143.
33. Simon D, Goretzki PE, Gorelev V, Ebling B, Reishaus E, Lyons J, Haubruck H, Röher HD 1994 Significance of P53 in human thyroid tumors. World J Surg 18:535-540; discussion 540-541.
34. Grosse J, Grimm D, Westphal K, Ulbrich C, Moosbauer J, Pohl F, Koelbl O, Infanger M, Eilles C, Schoenberger J 2009 Radiolabeled annexin V for imaging apoptosis in radiated human follicular thyroid carcinomas-is an individualized protocol necessary? Nucl Med Biol 36:89-98.
35. Dremier S, Golstein J, Mosselmans R, Dumont JE, Galand P, Robaye B 1994 Apoptosis in dog thyroid cells. Biochem Biophys Res Commun 15:52-58.
36. Moore D, Ohene-Fianko D, Garcia B, Chakrabarte S 1998 Apoptosis in thyroid carcinomas: relationship with p53 and bcl-2 expression. Histopathology 32:35-42.
37. Wischhusen J, Melino G, Weller M 2004 p53 and its family members-reporter genes may not see the difference. Cell death Differ 11:1150-1152.
38. Moretti F, Farsetti A, Soddu S, Crescenzi M, Filetti S, Andreoli M, Sacchi A, Pontecorvi A 1997 p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 14:729-740.
39. Narimatsu M, Nagayama Y, Akino K, Yasuda M, Yamamoto T, Yang TT, Ohtsuru A, Namba H, Yamashia S, Ayabe H, Niwa M 1998 Therapeutic usefulness of wild-type p53 gene introduction in p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab 83:3668-3672.